To predict arrhythmic risk in carriers of filamin C truncating variants, a novel risk predictive model was developed based on ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Neoantigen-targeting PCVs are highly immunogenic in high-risk clear cell RCC and can target key driver mutations and induce antitumor immunity.

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective provincial registry of PSMA PET/CT for recurrent prostate cancer. While most ...

The hormones you replace are not as protective as the hormone's you used to naturally produce, Shankar said. In fact, there ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a case-based session ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.